Denna sida på svenska
Loading profile information...

About me

I am an Assistant Professor in Molecular and Genetic Cancer Epidemiology at the Department of Biosciences and Nutrition.

 

My main scientific interest is in the search of understanding the specific patient and tumor characteristics required throughout tumor progression to enable the cancer tumor to gain early or late metastatic capacity, in the end responsible for virtually all cancer-related death. 

 

I focus my research around breast cancer that is the most common female cancer in the Western world. One in four women diagnosed with breast cancer will later develop distant metastatic disease and die. Breast cancer is widely recognized as a heterogeneous disease in the sense of both primary tumor metastatic capacity as well as time to metastatic spread of disease.

Education

  • MSc (Master of Science) in Molecular Biotechnology, Uppsala University. 
  • PhD in Cancer Epidemiology, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet.

Research description

Main research questions:

  • Does intra-tumor heterogeneity influence cancer patient survival and response to therapy?
  • Breast cancer in situ: Who is at high risk to develop invasive breast cancer?
  • Molecular definition of an “indolent” tumor? Identify patients at very low risk for fatal breast cancer.
  • Why do young women with breast cancer have poor prognosis?
  • Is breast cancer survival inherited?

Academic honours, awards and prizes

  • 3-year full Postdoctoral Research position from the Swedish Research Council (Vetenskapsrådet).
  • 4-year Young Investigator “Unga Forskare” Project Research Grant from the Swedish Research Council (Vetenskapsrådet).
  • 4-year Young Investigator Award from the Swedish Research Council for Health, Working life and Welfare (FORTE). 

Publications

Cause-specific mortality in women with breast cancer in situ
He W, Lindstrom Ls, Hall P, Czene K
INTERNATIONAL JOURNAL OF CANCER 2017;140(11):2414-2421

Differences in survival for patients with familial and sporadic cancer
Lee M, Reilly M, Lindström Ls, Czene K
International journal of cancer 2017;140(3):581-590

Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes
Li J, Ivansson E, Klevebring D, Tobin Np, Lindström Ls, Holm J, et al
Clinical cancer research : an official journal of the American Association for Cancer Research 2017;23(10):2584-2592

Site-specific familial risk and survival of familial and sporadic head and neck cancer
Renkonen S, Lee M, Mäkitie A, Lindström Ls, Czene K
International journal of cancer 2017;141(3):497-502

An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Tobin Np, Wennmalm K, Lindström Ls, Foukakis T, He L, Genové G, et al
Clinical cancer research : an official journal of the American Association for Cancer Research 2016;22(10):2417-26

Feasibility of reusing time-matched controls in an overlapping cohort
Delcoigne B, Hagenbuch N, Schelin Me, Salim A, Lindström Ls, Bergh J, et al
Statistical methods in medical research 2016;():-

Interobserver Agreement of Breast Cancer IHC4 after "Score the Core" Training
Borowsky A, Balassanian R, Yau C, Engelberg Ja, Thompson Ck, Retallack Heg, et al
LABORATORY INVESTIGATION 2016;:33A-33A

Interobserver Agreement of Breast Cancer IHC4 after "Score the Core" Training
Borowsky A, Balassanian R, Yau C, Engelberg Ja, Thompson Ck, Retallack Heg, et al
MODERN PATHOLOGY 2016;:33A-33A

Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse
Falato C, Tobin Np, Lorent J, Lindström Ls, Bergh J, Foukakis T
Molecular oncology 2016;10(4):517-25

Long-term outcome in young women with breast cancer: a population-based study
Fredholm H, Magnusson K, Lindström Ls, Garmo H, Fält Se, Lindman H, et al
Breast cancer research and treatment 2016;160(1):131-143

Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers
Li J, Holm J, Bergh J, Eriksson M, Darabi H, Lindström Ls, et al
Annals of oncology : official journal of the European Society for Medical Oncology 2015;26(3):517-22

Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications
Kimbung S, Kovács A, Danielsson A, Bendahl Po, Lövgren K, Frostvik Stolt M, et al
Oncotarget 2015;6(32):33306-18

Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer
Cunha Si, Bocci M, Lövrot J, Eleftheriou N, Roswall P, Cordero E, et al
Cancer research 2015;75(12):2445-56

Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer
Foukakis T, Lövrot J, Sandqvist P, Xie H, Lindström Ls, Giorgetti C, et al
Molecular oncology 2015;9(7):1384-91

Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer
Falato C, Tobin N, Lorent J, Lindstrom Ls, Bergh Jcs, Foukakis T
JOURNAL OF CLINICAL ONCOLOGY 2015;33(15):-

Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival - Retrospective analyses of the STO3 randomized trial
Lindstrom Ls, Yau C, Czene K, Thompson Ck, Van't Veer Lj, Nordenskjold B, et al
EUROPEAN JOURNAL OF CANCER 2015;:S269-S269

MammaPrint accurately predicts long-term survival (25 years) and adjuvant tamoxifen therapy benefit in lymph node negative patients
Lindstrom Ls, Benz Cc, Yau C, Van't Veer Lj, Thompson Ck, Esserman Lj
CANCER RESEARCH 2015;:-

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
Tobin Np, Harrell Jc, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, et al
Annals of oncology : official journal of the European Society for Medical Oncology 2015;26(1):81-8

2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
Li J, Lindström Ls, Foo Jn, Rafiq S, Schmidt Mk, Pharoah Pd, et al
Nature communications 2014;5():4051-

Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients
Tobin Np, Lindström Ls, Carlson Jw, Bjöhle J, Bergh J, Wennmalm K
Molecular oncology 2014;8(3):741-52

Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients (vol 8, pg 741, 2014)
Tobin Np, Lindstrom Ls, Carlson Jw, Bjohle J, Bergh J, Wennmalm K
MOLECULAR ONCOLOGY 2014;8(6):1159-1159

Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer
Lindström Ls, Li J, Lee M, Einbeigi Z, Hartman M, Hall P, et al
Annals of oncology : official journal of the European Society for Medical Oncology 2014;25(10):1966-72

Sequential metastatic biopsies and functional imaging in breast cancer
Foukakis T, Lovrot J, Sandqvist P, Xie Hj, Lindstrom Ls, Giorgetti C, et al
JOURNAL OF CLINICAL ONCOLOGY 2014;32(15):-

Gene signature model predicts metastatic onset better than standard clinical markers - Nested case-control design uniquely enables enrichment for biologically relevant features
Lindstrom Ls, Jauhiainen A, Wilking U, Foukakis T, Astrom G, Czene K, et al
CANCER RESEARCH 2013;:-

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
Lindstrom Ls, Karlsson E, Wilking Um, Johansson U, Hartman J, Lidbrink Ek, et al
JOURNAL OF CLINICAL ONCOLOGY 2012;30(21):2601-8

The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer
Rosin G, Hannelius U, Lindström L, Hall P, Bergh J, Hartman J, et al
BMC cancer 2012;12():79-

When to order a biopsy to characterise a metastatic relapse in breast cancer
Foukakis T, Astrom G, Lindstrom L, Hatschek T, Bergh J
ANNALS OF ONCOLOGY 2012;:x349-53

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, et al
BREAST CANCER RESEARCH AND TREATMENT 2011;125(2):553-61

Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer
Akhoondi S, Lindstrom L, Widschwendter M, Corcoran M, Bergh J, Spruck C, et al
BREAST CANCER RESEARCH 2010;12(6):R105-

Is Genetic Background Important in Lung Cancer Survival?
Lindstrom Ls, Hall P, Hartman M, Wiklund F, Czene K
PLOS ONE 2009;4(5):e5588-

Breast cancer onset in twins and women with bilateral disease
Hartman M, Hall P, Edgren G, Reilly M, Lindstrom L, Lichtenstein P, et al
JOURNAL OF CLINICAL ONCOLOGY 2008;26(25):4086-91

Etiology of familial aggregation in melanoma and squamous cell carcinoma of the skin
Lindstrom Ls, Yip B, Lichtenstein P, Pawitan Y, Czene K
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 2007;16(8):1639-43

Familial concordance in cancer survival: a Swedish population-based study
Lindstrom Ls, Hall P, Hartman M, Wiklund F, Gronberg H, Czene K
LANCET ONCOLOGY 2007;8(11):1001-6

Estimation of genetic and environmental factors for melanoma onset using population-based family data
Lindstrom L, Pawitan Y, Reilly M, Hemminki K, Lichtenstein P, Czene K
STATISTICS IN MEDICINE 2006;25(18):3110-23

Is breast cancer prognosis inherited?
Hartman M, Lindstrom L, Dickman Pw, Hall P, Czene K
BREAST CANCER RESEARCH AND TREATMENT 2006;:S185-S185

Show all publications

Map

Presentations

Telephone +46-08-524 88117